Literature DB >> 33381172

The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform.

Xia Sheng1, Guo-Hui Xiong2, Peng-Fei Yu3, Jian-Ping Liu3.   

Abstract

BACKGROUND: In recent years, the time of blood glucose within the target range is a new research hotspot in blood glucose management. TIR is expected to be a novel indicator for evaluating the efficacy of glycemic control and predicting diabetic complications. However, its relationship with diabetic complications has not been fully elucidated.
OBJECTIVE: To explore the relationship between time in range (TIR) and glycosylated hemoglobin (HbA1C) through the information big data management platform. Possible association between TIR and diabetic microvascular complications (retinopathy, nephropathy, and neuropathy) was investigated, attempting to provide theoretical basis for the clinical application of TIR and to explore the TIR control scope suitable for diabetic patients.
METHODS: A total of 5,644 type 2 diabetic patients hospitalized in the Department of Endocrinology, the Second Affiliated Hospital of Nanchang University, were selected from April 2017 to June 2020. Fingertip capillary blood glucose monitoring (FCGM) was monitored for a total of 455,664 times, and patients who are nondiabetic, pregnant, or with diabetic ketosis were excluded. Patients with 7 blood glucose points monitored for at least three consecutive days were selected as subjects in the study. 1,895 males and 1,513 females with diabetes were included, with an average age of (59.74 ± 13.40) years old and an average course of disease of 8.28 ± 7.11 years. The proportion of time in range (TIR) (70∼180 mg/dl) within the target range and the correlation between TIR and HbA1C were analyzed, as well as the relationship between TIR and the risk of diabetic complications.
RESULTS: (1) The average of TIR and HbA1C was 49.65 ± 23.36% and 8.92 ± 2.49%, respectively, and was linearly correlated. With the decrease of TIR, HbA1C increased significantly, and the difference was statistically significant (P < 0.01, R 2 = 0.458). The correlation coefficient of mean TIR with mean HbA1C was -0.626. (2) There were 836 patients diagnosed with diabetic nephropathy (DN). The difference of TIR value between DN and non-DN was significant (T = 2.250, P < 0.05). Risk assessment showed the lower the TIR was, the higher the risk of DN was. TIR less than 40% was a risk factor for DN (OR = 1.249, 95% CI: 0.915-1.375). (3) There were 1,296 patients diagnosed with diabetic peripheral neuropathy (DPN). The difference of TIR value between DPN and non-DPN was significant (T = 3.844, P < 0.01). TIR value less than 70% was a risk factor for DPN (OR = 1.030, 95% CI: 0.769-1.379). (4) There were 2,077 patients diagnosed with diabetic retinopathy (DR). The difference of TIR value between DPN and non-DPN was significant (T = 3.608, P < 0.01). TIR value less than 50% was a risk factor for DR (OR = 1.092, 95% CI: 0.898-1.264). Summary. TIR may serve as a reference index for short-term blood glucose control, strongly reflecting the clinical blood glucose regulation and predicting the risk of diabetic microvascular complications.
Copyright © 2020 Xia Sheng et al.

Entities:  

Year:  2020        PMID: 33381172      PMCID: PMC7755494          DOI: 10.1155/2020/8879085

Source DB:  PubMed          Journal:  Int J Endocrinol        ISSN: 1687-8337            Impact factor:   3.257


  13 in total

1.  The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.

Authors:  Robert A Vigersky; Chantal McMahon
Journal:  Diabetes Technol Ther       Date:  2018-12-21       Impact factor: 6.118

2.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading.

Authors:  Roy W Beck; Crystal G Connor; Deborah M Mullen; David M Wesley; Richard M Bergenstal
Journal:  Diabetes Care       Date:  2017-08       Impact factor: 19.112

Review 3.  Positioning time in range in diabetes management.

Authors:  Andrew Advani
Journal:  Diabetologia       Date:  2019-11-07       Impact factor: 10.122

4.  It's time to move from the A1c to better metrics for diabetes control.

Authors:  Aaron J Kowalski; Sanjoy Dutta
Journal:  Diabetes Technol Ther       Date:  2013-03-01       Impact factor: 6.118

5.  The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c.

Authors:  Roy W Beck; Richard M Bergenstal; Peiyao Cheng; Craig Kollman; Anders L Carlson; Mary L Johnson; David Rodbard
Journal:  J Diabetes Sci Technol       Date:  2019-01-13

6.  Use of continuous glucose monitoring as an outcome measure in clinical trials.

Authors:  Roy W Beck; Peter Calhoun; Craig Kollman
Journal:  Diabetes Technol Ther       Date:  2012-10       Impact factor: 6.118

7.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

8.  The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial.

Authors: 
Journal:  Diabetes       Date:  1995-08       Impact factor: 9.461

9.  Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes.

Authors:  Jingyi Lu; Xiaojing Ma; Jian Zhou; Lei Zhang; Yifei Mo; Lingwen Ying; Wei Lu; Wei Zhu; Yuqian Bao; Robert A Vigersky; Weiping Jia
Journal:  Diabetes Care       Date:  2018-09-10       Impact factor: 19.112

Review 10.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Authors:  Tadej Battelino; Thomas Danne; Richard M Bergenstal; Stephanie A Amiel; Roy Beck; Torben Biester; Emanuele Bosi; Bruce A Buckingham; William T Cefalu; Kelly L Close; Claudio Cobelli; Eyal Dassau; J Hans DeVries; Kim C Donaghue; Klemen Dovc; Francis J Doyle; Satish Garg; George Grunberger; Simon Heller; Lutz Heinemann; Irl B Hirsch; Roman Hovorka; Weiping Jia; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; Brian Levine; Alexander Mayorov; Chantal Mathieu; Helen R Murphy; Revital Nimri; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; David Rodbard; Banshi Saboo; Desmond Schatz; Keaton Stoner; Tatsuiko Urakami; Stuart A Weinzimer; Moshe Phillip
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

View more
  6 in total

Review 1.  When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD.

Authors:  Alba Rojano-Toimil; Jesús Rivera-Esteban; Ramiro Manzano-Nuñez; Juan Bañares; David Martinez Selva; Pablo Gabriel-Medina; Roser Ferrer; Juan M Pericàs; Andreea Ciudin
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

Review 2.  Diabetes: how to manage diabetic peripheral neuropathy.

Authors:  Megha Gandhi; Emily Fargo; Lalita Prasad-Reddy; Katherine M Mahoney; Diana Isaacs
Journal:  Drugs Context       Date:  2022-06-14

3.  Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review.

Authors:  Rishi Raj; Vivek Joshi; Rahul Mishra; Nivedita Jha; Ricardo Correa; Philip A Kern
Journal:  BMJ Open Diabetes Res Care       Date:  2022-01

4.  Impact of time in range during hospitalization on clinical outcomes in diabetic patients with toe amputation: a propensity score matching analysis.

Authors:  Su Li; Ze-Xin Huang; Dong-Hao Lou; Ye-Yong Jiang; Sheng Zhao
Journal:  BMC Surg       Date:  2022-08-12       Impact factor: 2.030

5.  Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring.

Authors:  Charalampos Margaritidis; Eleni Karlafti; Evangelia Kotzakioulafi; Konstantinos Kantartzis; Konstantinos Tziomalos; Georgia Kaiafa; Christos Savopoulos; Triantafyllos Didangelos
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

6.  Frequent scanning using flash glucose monitoring contributes to better glycemic control in children and adolescents with type 1 diabetes.

Authors:  Tatsuhiko Urakami; Kei Yoshida; Remi Kuwabara; Yusuke Mine; Masako Aoki; Junichi Suzuki; Ichiro Morioka
Journal:  J Diabetes Investig       Date:  2021-07-17       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.